The largest database of trusted experimental protocols

3 protocols using mm 1s

1

Cultivating and Treating Multiple Myeloma Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
The human MM cell lines NCI-H929, RPMI 8226 and MM.1S were purchased from ATCC and authenticated by them; all were used within <6 months of post-receipt cultivation. Cells were maintained in RPMI 1640 medium with L-glutamine and NaHCO3 (ATCC) containing 10% FBS (ATCC), 100U/mL of penicillin and 100 μg/mL of streptomycin (Sigma-Aldrich). MM.1S-DR.GFP cells (kindly provided by Dr. Nizar Bahlis, Univ. of Calgary, Canada), were derived from the MM.1S line but not authenticated by us, were maintained in the same medium but supplemented with 2 μg/mL puromycin (Sigma-Aldrich). Normal human peripheral blood CD19+ B cells (ZenBio) were cultured in ZenBio Lymphocyte medium.
ABT-888 (Santa Cruz Biotechnology, Inc.), doxorubicin-HCl (Sigma Aldrich) and dinaciclib (SCH727965; ChemieTek) were dissolved in DMSO. The stock drug concentrations were diluted in cell-culture medium prior to cell treatment. For in vivo studies, dinaciclib was dissolved in 15% Captisol® (Ligand Pharmaceuticals, Inc.).
+ Open protocol
+ Expand
2

Cell Culture and XPO1 SINE Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following cell lines (ATCC, except where noted) were grown in culture medium supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco), 100 units/mL penicillin, 100 μg/mL streptomycin (Gibco), and 1x GlutaMAX (Gibco) (except where noted), and maintained in a humidified incubator at 37°C in 5% CO2; Rev-GFP U2OS [McCoy's 5A, 200 ug/ml G418 (Sigma)], MM.1S (RPMI), MV-4–11 (IMDM), THP-1 (RPMI), HCT-116 (McCoy's 5A), AML2 (DSMZ, RPMI), AML3 (DSMZ, RPMI), HT1080 (EMEM), HEL (DSMZ, RPMI), Kasumi-6 (RPMI, 2 mM L-glutamine, 1.5g/L sodium biocarbonate, 4.5 g/L glucose, 10 mM HEPES, 1.0 mM sodium pyruvate, 2 ng/mL GM-CSF, 20% FBS), SINE compound resistant HT1080 (EMEM, 600 nM KPT-185), A549 (RPMI), UCH1 (4:1 IMDM:RPMI), UCH2 (4:1 IMDM:RPMI), LS174T (EMEM), and ASPS-KY (gifted from A. Ogose, RPMI). The XPO1 SINE™ compounds KPT-330 (selinexor), KPT-335, KPT-350, KPT-8602, KPT-301, KPT-9159 (biotinylated LMB, b-LMB), KPT-9058 (biotinylated KPT-276), and KPT-9511 (biotinylated KPT-8602) were synthesized at Karyopharm Therapeutics, Inc. (Newton, MA). LMB was purchased from Cell Signaling.
+ Open protocol
+ Expand
3

Cell Culture Conditions of Various Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Jeko-1, Mino, MM.1S, and HEK293T cells were bought from the American Type Culture Collection (ATCC), and DAOY cells were a gift from Dr. Alex Huang (Case Western Reserve University, OH, USA). Jeko-1, Mino, MM.1S, and DAOY cells were cultured in RPMI-1640 (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich) and 1% Pen/Strep (Hyclone). HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Sigma-Aldrich) with the same 10% FBS and 1% Pen/Strep supplementation. NK92 cells were a kind gift from Dr. Daniel Popkin (Innova Dermatology, TN, USA). They were cultured in Alpha-MEM media (Sigma-Aldrich) and supplemented with 12.5% FBS, 12.5% horse serum (Sigma-Aldrich), 0.02 mM folic acid (Acros), 0.1 mM 2-mercaptoethanol (Gibco), 1.5 g/L sodium bicarbonate (Fisher Scientific), 2 mM L-glutamine (Gibco), and 0.2 mM inositol (Acros). IL-2 (200 IU) was added fresh ever 2–3 days with media changes for NK92 cells. All cells were maintained at 37°C with 5% CO2 in the cell incubator. Glucose concentrations of media used for cell culture: 2 g/L for primary NK cells, as they were in RPMI-1640 media; 1g/L for NK92 cells, as they were cultured in Alpha-MEM; and 4.5 g/L for HEK293T cells, as we use DMEM-High Glucose. All media are from Sigma-Aldrich as mentioned above.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!